2254-2255 / 2437
Costa
et al 2015, J Clin Oncol; 33 (17): 1881-1888
PROFILE trials
Phase II
730 patients
ALK+ advanced NSCLC
Crizotinib
Brain metastases in patients with ALK-positive NSCLC
randomise
Crizotinib
158 patients
chemotherapy
PROFILE 1005
PROFILE 1007